The Latest Breaking News from GVB Biopharma

22nd Century Group Q3 Revenue Grows 148% YoY, Here Are The Details

22nd Century Group, Inc. (NASDAQ: XXII) net revenues for the third quarter of 2022 were $19.4 million, an increase of 148.2% from 2021.

Benzinga · Nov 8, 2022

Cannabis Movers & Shakers: 22nd Century Group, Houseplant, Proven Media

22nd Century Group Names New CFO 22nd Century Group (NASDAQ: XXII) has appointed f R. Hugh Kinsman to oversee its financial department. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022.

Benzinga · Jun 17, 2022

22nd Century Group Acquires Privately-Held Cannabis & Hemp Co., Here's What's Next

22nd Century Group, Inc. (NASDAQ: XXII) announced the acquisition of privately held GVB Biopharma. GVB - a contract development and manufacturing organization - provides hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide.

Benzinga · May 13, 2022